UniProt ID: P10415
Gene: BCL2
Molecular Weight: 26 kDa
Subcellular Localization: Mitochondrial outer membrane, ER, nuclear envelope
Protein Family: BCL-2 family (anti-apoptotic subfamily)
Key Domains:
BCL2 (B-Cell Lymphoma 2) is the founding member of the BCL-2 protein family and a central regulator of the intrinsic (mitochondrial) apoptosis pathway[1]. As an anti-apoptotic protein, BCL2 protects cells from programmed cell death by preventing mitochondrial outer membrane permeabilization (MOMP) and cytochrome c release[2]. In neurodegeneration, BCL2 dysfunction contributes to neuronal vulnerability, while therapeutic strategies aim to enhance BCL2 activity to protect neurons from apoptosis[3].
BCL2 contains four BCL-2 homology domains that mediate protein-protein interactions[4]:
| Domain | Residues | Function |
|---|---|---|
| BH4 | 10-30 | Anti-apoptotic function; stabilizes structure |
| BH3 | 93-107 | Pro-apoptotic protein binding groove |
| BH1 | 136-155 | Hydrophobic groove formation |
| BH2 | 187-202 | Completes binding groove |
| TM | 219-239 | Membrane anchoring |
BCL2 adopts a globular fold with[5]:
BCL2 localizes primarily to[6]:
The transmembrane domain anchors BCL2 to these membranes, positioning it to regulate apoptosis.
The BCL-2 family is divided into three functional groups[7]:
BCL2 inhibits apoptosis through multiple mechanisms[8]:
Direct BAX/BAK inhibition
BH3-only protein sequestration
Mitochondrial membrane stabilization
At the ER, BCL2[9]:
BCL2 binds Beclin-1 (ATG6) and[10]:
BCL2 dysregulation in AD includes[11]:
Findings:
Consequences:
In PD, BCL2 plays a protective role[12]:
Evidence:
Mutant huntingtin affects BCL2[13]:
BCL2 is neuroprotective in cerebral ischemia[14]:
Motor neurons show BCL2 abnormalities[15]:
| Approach | Agent/Mechanism | Status |
|---|---|---|
| Gene therapy | AAV-BCL2 delivery | Preclinical |
| Pharmacologic upregulation | HDAC inhibitors, retinoids | Research stage |
| BH3 mimetics (cancer) | Venetoclax (BCL2 inhibitor) | FDA-approved (cancer); NOT for neurodegeneration |
| Peptide inhibitors | Stapled peptides | Research stage |
Important distinction: BH3 mimetics (like venetoclax) INHIBIT BCL2 and are used in cancer to promote tumor cell death. For neurodegeneration, the opposite approach is needed – enhancing BCL2 activity or expression[16].
| Context | Strategy | Goal |
|---|---|---|
| Cancer | BCL2 inhibition | Kill cancer cells |
| Neurodegeneration | BCL2 enhancement | Protect neurons |
| Partner | Function | Disease Relevance |
|---|---|---|
| BAX | Pro-apoptotic effector | MOMP execution |
| BAK | Pro-apoptotic effector | MOMP execution |
| BIM | BH3-only activator | Stress sensing |
| tBID | Truncated BID | Death receptor pathway |
| BAD | BH3-only sensitizer | Growth factor signaling |
| Beclin-1 | Autophagy regulator | Autophagy inhibition |
| IP3R | Calcium channel | ER calcium regulation |
BCL2 transcription is regulated by[17]:
| Modification | Site | Effect |
|---|---|---|
| Phosphorylation | Ser70 | Activity regulation |
| Phosphorylation | Thr69 | Reduced function |
| Ubiquitination | Various | Proteasomal degradation |
| Oxidation | Cys residues | Loss of function |
BCL2 stability is influenced by:
BCL2 transgenic mice[18]:
BCL2 knockout mice:
Tsujimoto et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984. ↩︎
Kroemer & Reed. Mitochondrial control of cell death. Nature Medicine. 2000. ↩︎
Cory & Adams. The Bcl2 family: regulators of the cellular life-or-death switch. Nature Reviews Cancer. 2002. ↩︎
Youle & Strasser. The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology. 2008. ↩︎
Petros et al. Solution structure of the antiapoptotic protein BCL-2. PNAS. 1996. ↩︎
Krajewski et al. Immunohistochemical analysis of the Bcl-2 protein in human tissues. American Journal of Anatomy. 1997. ↩︎
Czabotar et al. BCL-2 family proteins in apoptosis. Nature Reviews Molecular Cell Biology. 2014. ↩︎
Edlich et al. Bcl-2 family proteins and cancer. Oncotarget. 2011. ↩︎
Rong et al. Bcl-2 family proteins regulate Ca2+ release from IP3 receptors. Journal of Biological Chemistry. 1999. ↩︎
Pattingre et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005. ↩︎
MacGibbon et al. [BCL2 in Alzheimer's disease](https://doi.org/10.1016/s0896-6273(00). Journal of Neuropathology & Experimental Neurology. 1997. ↩︎
Offen et al. [BCL-2 protects dopaminergic neurons](https://doi.org/10.1016/s0896-6273(00). Journal of Neuroscience. 1998. ↩︎
Chen et al. Mutant huntingtin decreases BCL2 expression. Journal of Biological Chemistry. 2008. ↩︎
Martinou et al. [Bcl-2 transgenic mice show reduced infarct size](https://doi.org/10.1016/0896-6273(94). Neuron. 1994. ↩︎
Mu et al. BCL2 in ALS. Acta Neuropathologica. 2006. ↩︎
Ashkenazi et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nature Reviews Drug Discovery. 2022. ↩︎
Kirsch et al. Transcriptional regulation of Bcl-2. Journal of Neurochemistry. 1999. ↩︎
Dubois-Dauphin et al. [Neuronal overexpression of Bcl-2 protects against axotomy](https://doi.org/10.1016/0896-6273(94). Neuroscience. 1994. ↩︎